Rohto Pharmaceutical Co.,Ltd.
RPHCF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $308,625,000 | $270,840,000 | $238,664,000 | $199,646,000 |
| % Growth | 14% | 13.5% | 19.5% | – |
| Cost of Goods Sold | $133,686,000 | $113,554,000 | $779,285 | $702,777 |
| Gross Profit | $174,939,000 | $157,286,000 | $1,017,139 | $937,315 |
| % Margin | 56.7% | 58.1% | 0.4% | 0.5% |
| R&D Expenses | $14,912,000 | $13,390,000 | $83,663 | $72,136 |
| G&A Expenses | $0 | $0 | -$45,785,965 | -$37,477,674 |
| SG&A Expenses | $57,506,000 | $54,219,000 | $681,035 | $636,326 |
| Sales & Mktg Exp. | $57,506,000 | $54,219,000 | $46,467,000 | $38,114,000 |
| Other Operating Expenses | $63,582,000 | $49,629,000 | $0 | $0 |
| Operating Expenses | $136,000,000 | $117,238,000 | $764,698 | $708,462 |
| Operating Income | $38,939,000 | $40,048,000 | $33,959,000 | $29,015,000 |
| % Margin | 12.6% | 14.8% | 14.2% | 14.5% |
| Other Income/Exp. Net | $3,392,000 | $1,470,000 | $331,000 | -$1,141,000 |
| Pre-Tax Income | $42,331,000 | $41,518,000 | $34,290,000 | $27,874,000 |
| Tax Expense | $11,379,000 | $10,123,000 | $7,860,000 | $6,686,000 |
| Net Income | $31,006,000 | $30,936,000 | $26,377,000 | $21,127,000 |
| % Margin | 10% | 11.4% | 11.1% | 10.6% |
| EPS | 136.11 | 135.6 | 115.62 | 92.61 |
| % Growth | 0.4% | 17.3% | 24.8% | – |
| EPS Diluted | 135.44 | 135.21 | 115.29 | 92.34 |
| Weighted Avg Shares Out | 227,801 | 228,138 | 228,139 | 228,140 |
| Weighted Avg Shares Out Dil | 228,928 | 228,798 | 228,798 | 228,799 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,223,000 | $1,523,000 | $962,000 | $368,000 |
| Interest Expense | $949,000 | $196,000 | $247,000 | $248,000 |
| Depreciation & Amortization | $13,143,000 | $8,687,000 | $7,801,000 | $7,689,000 |
| EBITDA | $56,423,000 | $50,401,000 | $42,338,000 | $35,811,000 |
| % Margin | 18.3% | 18.6% | 17.7% | 17.9% |